SCHEMBL5199891

SCHEMBL5199891

Cc1cccc(-c2n[nH]cc2-c2ccc(F)c(-c3ccc(N4CCOCC4)nc3)c2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 7/20 0.49
TDO2 P48775 1/20 0.45
ADK P55263 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
CASP1 P29466 1/20 0.41
BLM P54132 1/20 0.41
CASP7 P55210 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MAP4K1 Q92918 1/20 0.40
PDE10A Q9Y233 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5198525 0.90 TDO2 (0.46) TDO2MAP4K1TGFBR1BRD4CREBBP
SCHEMBL5200213 0.85 BRD9 (0.38) KDM4EALDH1A1MAPTMAP4K1TGFBR1
SCHEMBL5199757 0.81 JAK2 (0.42) CNR2TGFBR1
SCHEMBL5200249 0.80 CNR1 (0.41) CNR2MAP4K1TGFBR1
SCHEMBL5232325 0.80 CYP2D6 (0.42) KMT2ASMN1; SMN2TGFBR1
SCHEMBL5200014 0.80 TGFBR1 (0.53) TGFBR1
SCHEMBL5199272 0.79 CNR2 (0.42) CNR2ADKKDM4EMEN1ALDH1A1
SCHEMBL5198540 0.79 TGFBR1 (0.39) CNR2TGFBR1
SCHEMBL5198175 0.78 BMPR1A (0.45) CNR2TGFBR1
SCHEMBL5199156 0.78 MEN1 (0.40) MEN1KMT2ASMN1; SMN2TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275968-A1 Substituted Biphenyl Derivative SANKYO COMPANY, LIMITED (JP) 2007-11-29 US disclosed
EP-1798229-A1 SUBSTITUTED BIPHENYL DERIVATIVE Sankyo Company, Limited (JP) 2007-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275968-A1 Substituted Biphenyl Derivative COL2A1, COL1A1, FGFR3 CNR2 161/4885TDO2 1082/4885ADK 4659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.